20:
139:
Bone lesions in multiple myeloma patients may be treated with low-dose radiation therapy in order to reduce pain and other symptoms. Used in combination with immunochemotherapy, radiation therapy can be used to treat certain cancers when aimed at areas of bone lesion and softened bone.
89:
The most common cancers that metastasize to form osteolytic lesions are thyroid, lung, kidney, gastrointestinal, malignant melanoma and breast, though any cancer can cause bone lesions. Lesions are most often found in larger bones, such as the skull, pelvis, radius, and femur.
110:
is a specific drug given to cancer patients to prevent the worsening of bone lesions and has been reported to have anti-tumor effects as well. Zoledronic acid has been clinically tested in conjunction with calcium and vitamin D to encourage bone health.
86:, causing an increasing in bone tissue resorption and an overall breakdown of bone integrity. This breakdown often begins in the bone marrow near tumor sites and spreads outward to the surface of the implicated bone.
131:
gene, is also prescribed to prevent bone metastases and bone lesions. Most biophosphonates are co-prescribed with disease-specific treatments, such as chemotherapy or radiation for cancer patients.
205:
63:. This imbalance is due to a flooding of regulatory factors released by specific tumors, thus overwhelming the tissue repair system and resulting in these lesions. The over-activity of
59:
Bone lesions are caused by an imbalance of regulatory factors, characterized by an increased depletion and resorption of old bone tissue and a decrease in bone rebuilding, known as
186:
Matsumoto, Toshio; Kido, Shinsuke; Inoue, Daisuke; Oshima, Takashi; Abe, Masahiro (2004). "Myeloma-Bone
Interaction for the Development of Myeloma Bone Disease".
31:(from the Greek words for "bone" (ὀστέον), and "to unbind" (λύειν)) is a softened section of a patient's bone formed as a symptom of specific diseases, including
343:
213:
43:
due to decreased bone density, although many other diseases are associated with this symptom. Osteolytic lesions can cause pain, increased risk of
368:"Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma - Full Text View - ClinicalTrials.gov"
367:
243:
51:. These lesions can be treated using biophosphonates or radiation, though new solutions are being tested in clinical trials.
393:"Case of polyostotic primary bone lymphoma successfully treated with immunochemotherapy and consolidation radiotherapy"
261:"Remarkable Regression of an Osteolytic Lesion of Large Cell Lung Cancer Treated with Zoledronic Acid: A Case Report"
316:
23:
Osteolytic lesion at the bottom of the radius, diagnosed by a darker section that indicates a loss of bone density
317:"Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I - Full Text View - ClinicalTrials.gov"
82:
from creating new bone, while these cancerous cells also release factors that cause an upregulation on
459:
162:
106:
are drugs that are used to prevent bone mass loss and are often used to treat osteolytic lesions.
48:
71:, which can cause damage to the kidneys and requires additional medication and monitoring.
8:
116:
425:
392:
293:
260:
430:
412:
391:
Ahmad, Irfan; Chufal, Kundan Singh; Goyal, Nidhi; Bhatt, Chandi Prasad (2017-03-01).
298:
280:
239:
454:
420:
404:
288:
272:
75:
36:
120:
107:
60:
259:
Kawai, Sadayuki; Yamaura, Gengo; Yasuda, Katsuhiro; Suzuki, Takao (2012-05-10).
103:
68:
448:
416:
284:
206:"Round 2 : Treatment of Metastatic Bone Disease • Arthritis Information"
44:
32:
19:
408:
434:
302:
83:
79:
64:
276:
124:
112:
344:"Multiple Myeloma Bone Disease Treatment - Bone Disease Treatments"
163:"Myeloma Bone Lesions - Lytic Bone Lesions - Bone Lesion Myeloma"
128:
40:
258:
185:
390:
446:
78:, an increased number of myeloma cells block
39:. This softened area appears as a hole on
424:
292:
18:
93:
447:
233:
348:Multiple Myeloma Research Foundation
338:
336:
188:Journal of Bone and Mineral Research
167:Multiple Myeloma Research Foundation
157:
155:
153:
13:
98:
54:
14:
471:
333:
194:(9): 1559–1600 – via Wiley.
150:
384:
360:
309:
252:
227:
198:
179:
1:
143:
134:
7:
236:Pathologic Basis of Disease
10:
476:
16:Softened section of a bone
108:Zoledronic acid (Reclast)
265:Case Reports in Oncology
409:10.1136/bcr-2016-218832
49:spinal cord compression
24:
234:Kumar, Vinay (2014).
210:Arthritis Information
127:apoptosis regulatory
22:
94:Potential treatments
117:monoclonal antibody
372:clinicaltrials.gov
321:clinicaltrials.gov
25:
403:: bcr2016218832.
277:10.1159/000339125
245:978-1-4557-2613-4
123:that targets the
29:osteolytic lesion
467:
439:
438:
428:
397:BMJ Case Reports
388:
382:
381:
379:
378:
364:
358:
357:
355:
354:
340:
331:
330:
328:
327:
313:
307:
306:
296:
256:
250:
249:
238:. p. 1207.
231:
225:
224:
222:
221:
212:. Archived from
202:
196:
195:
183:
177:
176:
174:
173:
159:
76:multiple myeloma
37:multiple myeloma
475:
474:
470:
469:
468:
466:
465:
464:
460:Skeletal system
445:
444:
443:
442:
389:
385:
376:
374:
366:
365:
361:
352:
350:
342:
341:
334:
325:
323:
315:
314:
310:
257:
253:
246:
232:
228:
219:
217:
204:
203:
199:
184:
180:
171:
169:
161:
160:
151:
146:
137:
121:RANKl inhibitor
104:Bisphosphonates
101:
99:Bisphosphonates
96:
67:can also cause
61:bone remodeling
57:
55:Cellular causes
17:
12:
11:
5:
473:
463:
462:
457:
441:
440:
383:
359:
332:
308:
271:(2): 233–237.
251:
244:
226:
197:
178:
148:
147:
145:
142:
136:
133:
100:
97:
95:
92:
56:
53:
15:
9:
6:
4:
3:
2:
472:
461:
458:
456:
453:
452:
450:
436:
432:
427:
422:
418:
414:
410:
406:
402:
398:
394:
387:
373:
369:
363:
349:
345:
339:
337:
322:
318:
312:
304:
300:
295:
290:
286:
282:
278:
274:
270:
266:
262:
255:
247:
241:
237:
230:
216:on 2020-04-04
215:
211:
207:
201:
193:
189:
182:
168:
164:
158:
156:
154:
149:
141:
132:
130:
126:
122:
118:
114:
109:
105:
91:
87:
85:
81:
77:
72:
70:
69:hypercalcemia
66:
62:
52:
50:
46:
45:bone fracture
42:
38:
34:
33:breast cancer
30:
21:
400:
396:
386:
375:. Retrieved
371:
362:
351:. Retrieved
347:
324:. Retrieved
320:
311:
268:
264:
254:
235:
229:
218:. Retrieved
214:the original
209:
200:
191:
187:
181:
170:. Retrieved
166:
138:
102:
88:
73:
58:
28:
26:
84:osteoclasts
80:osteoblasts
65:osteoclasts
41:X-ray scans
449:Categories
377:2017-03-14
353:2017-03-14
326:2017-04-10
220:2017-04-10
172:2017-03-14
144:References
119:treatment
417:1757-790X
285:1662-6575
135:Radiation
125:osteocyte
113:Denosumab
435:28249886
303:22679429
455:Lesions
426:5353460
294:3369252
433:
423:
415:
301:
291:
283:
242:
47:, and
129:RANKL
431:PMID
413:ISSN
401:2017
299:PMID
281:ISSN
240:ISBN
115:, a
35:and
421:PMC
405:doi
289:PMC
273:doi
74:In
27:An
451::
429:.
419:.
411:.
399:.
395:.
370:.
346:.
335:^
319:.
297:.
287:.
279:.
267:.
263:.
208:.
192:19
190:.
165:.
152:^
437:.
407::
380:.
356:.
329:.
305:.
275::
269:5
248:.
223:.
175:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
